Literature DB >> 22167276

Increased arterial stiffness is associated with high cardiovascular mortality in male Fabry patients.

Kathleen Nicholls1.   

Abstract

Cardiovascular survival in a cohort of 33 male Fabry patients followed for a median of 7.3 years at a single centre was most strongly associated in a Cox proportional hazard regression model with age and elevated arterial stiffness at baseline. Seven patients died of cardiovascular causes. The presence of cardiomyopathy and renal involvement (either clinical nephropathy or CKD stage >1) were also negatively associated with survival when analysed as single factors. In this small study, presence of hypertension and hypercholesterolemia at baseline did not significantly predict cardiovascular death. The significant effect of elevated arterial stiffness, especially in a small cohort, argues for its clinical utility in individual patient risk assessment and for further intervention studies focusing on therapeutic reduction.

Entities:  

Mesh:

Year:  2011        PMID: 22167276     DOI: 10.1007/s10545-011-9428-z

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  20 in total

1.  Natural history of Fabry disease in affected males and obligate carrier females.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

Review 2.  Mechanisms, pathophysiology, and therapy of arterial stiffness.

Authors:  Susan J Zieman; Vojtech Melenovsky; David A Kass
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-02-24       Impact factor: 8.311

3.  Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT).

Authors:  Carmel M McEniery; Ian R Hall; Ahmad Qasem; Ian B Wilkinson; John R Cockcroft
Journal:  J Am Coll Cardiol       Date:  2005-10-10       Impact factor: 24.094

4.  Onset and progression of the Anderson-Fabry disease related cardiomyopathy.

Authors:  Christoph Kampmann; Ales Linhart; Frank Baehner; Tomas Palecek; Christiane M Wiethoff; Elke Miebach; Catharina Whybra; Andreas Gal; Jan Bultas; Michael Beck
Journal:  Int J Cardiol       Date:  2008-06-24       Impact factor: 4.164

5.  Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies.

Authors:  R Asmar; A Benetos; J Topouchian; P Laurent; B Pannier; A M Brisac; R Target; B I Levy
Journal:  Hypertension       Date:  1995-09       Impact factor: 10.190

6.  Aortic stiffness is an independent predictor of fatal stroke in essential hypertension.

Authors:  Stéphane Laurent; Sandrine Katsahian; Céline Fassot; Anne-Isabelle Tropeano; Isabelle Gautier; Brigitte Laloux; Pierre Boutouyrie
Journal:  Stroke       Date:  2003-04-03       Impact factor: 7.914

7.  Clinical benefit of enzyme replacement therapy in Fabry disease.

Authors:  F Breunig; F Weidemann; J Strotmann; A Knoll; C Wanner
Journal:  Kidney Int       Date:  2006-04       Impact factor: 10.612

8.  Agalsidase alfa and kidney dysfunction in Fabry disease.

Authors:  Michael West; Kathy Nicholls; Atul Mehta; Joe T R Clarke; Robert Steiner; Michael Beck; Bruce A Barshop; William Rhead; Robert Mensah; Markus Ries; Raphael Schiffmann
Journal:  J Am Soc Nephrol       Date:  2009-04-08       Impact factor: 10.121

9.  Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.

Authors:  Ales Linhart; Christoph Kampmann; José L Zamorano; Gere Sunder-Plassmann; Michael Beck; Atul Mehta; Perry M Elliott
Journal:  Eur Heart J       Date:  2007-05-05       Impact factor: 29.983

10.  Impact of aortic stiffness on survival in end-stage renal disease.

Authors:  J Blacher; A P Guerin; B Pannier; S J Marchais; M E Safar; G M London
Journal:  Circulation       Date:  1999-05-11       Impact factor: 29.690

View more
  1 in total

Review 1.  The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts.

Authors:  Dominique P Germain; Perry M Elliott; Bruno Falissard; Victor V Fomin; Max J Hilz; Ana Jovanovic; Ilkka Kantola; Aleš Linhart; Renzo Mignani; Mehdi Namdar; Albina Nowak; João-Paulo Oliveira; Maurizio Pieroni; Miguel Viana-Baptista; Christoph Wanner; Marco Spada
Journal:  Mol Genet Metab Rep       Date:  2019-02-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.